

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
31 December 2003 (31.12.2003)

PCT

(10) International Publication Number
WO 2004/000825 A1

(51) International Patent Classification⁷: **C07D 295/182**,
211/66, 217/12, 309/32, A61K 31/495, 31/5375, 31/472,
A61P 37/00

GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC,
SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG,
US, UZ, VC, VN, YU, ZA, ZM, ZW.

(21) International Application Number:
PCT/SE2003/001080

(22) International Filing Date: 23 June 2003 (23.06.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data: 24 Dec 04
0201977-6 24 June 2002 (24.06.2002) SE

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declaration under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)

(71) Applicant (for all designated States except US): AS-TRAZENECA AB [SE/SE]; S-151 85 Södertälje (SE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): BAILEY, Andrew [GB/GB]; AstraZeneca R & D Charnwood, Bakewell Road, Loughborough, Leicestershire LE11 5RH (GB). PAIRAUDEAU, Garry [GB/GB]; AstraZeneca R & D Charnwood, Bakewell Road, Loughborough, Leicestershire LE11 5RH (GB). PATEL, Anil [GB/GB]; AstraZeneca R & D Charnwood, Bakewell Road, Loughborough, Leicestershire LE11 5RH (GB). THOM, Stephen [GB/GB]; AstraZeneca R & D Charnwood, Bakewell Road, Loughborough, Leicestershire LE11 5RH (GB).

(74) Agent: GLOBAL INTELLECTUAL PROPERTY; AstraZeneca AB, S-151 85 Södertälje (SE).


(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,

Published:

— with international search report
— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: NOVEL COMPOUNDS



(I)

(57) Abstract: The present invention relates to compounds and compositions for treating diseases associated with cysteine protease activity. The compounds are reversible inhibitors of cysteine proteases S, K, F, L and B. Of particular interest are diseases associated with Cathepsin S. In addition this invention also discloses processes for the preparation of such inhibitors. (I) in which: A is a 6-membered ring optionally containing a double bond and optionally containing an oxygen atom or NR group in the ring;

NOVEL COMPOUNDS


The present invention relates to compounds and compositions for treating diseases associated with cysteine protease activity. The compounds are reversible inhibitors of cysteine proteases S, K, F, L and B. Of particular interest are diseases associated with Cathepsin S. In addition this invention also discloses processes for the preparation of such inhibitors.

BACKGROUND OF THE INVENTION

Cathepsin S is a member of the papain superfamily of cysteine proteases which also encompasses Cathepsins B, H, L, O and K. Cathepsin S plays a key role in the processing of invariant chain in MHC class II complexes allowing the complex to associate with antigenic peptides. MHC class II complexes are then transported to the surface of the cell for presentation to effector cells such as T cells. The process of antigen presentation is a fundamental step in initiation of the immune response. In this respect inhibitors of cathepsin S could be useful agents in the treatment of inflammation and immune disorders such as, but not limited to, asthma, rheumatoid arthritis, multiple sclerosis and Crohn's disease. Cathepsin S has also been implicated in a variety of other diseases involving extracellular proteolysis such as the development of emphysema in COPD through degradation of elastin and in Alzheimers disease.

Other Cathepsins notably K and L have been shown to degrade bone collagen and other bone matrix proteins. Inhibitors of these cysteine proteases would be expected to be useful in the treatment of diseases involving bone resorption such as osteoporosis.

The present invention therefore provides use of a compound of formula (I)



(I)

5 in which:

A is a 6-membered ring optionally containing a double bond and optionally containing an oxygen atom or NR group in the ring;

R is hydrogen or C₁₋₆ alkyl;

10 R¹ and R² are independently, C₁₋₆ alkyl or C₃₋₆ cycloalkyl both of which can optionally contain one or more O, S or NR³ groups, or R¹ and R² together with the nitrogen atom to which they are attached form a 3,4-dihydroisoquinoline ring or a 5- or 6-membered saturated ring optionally containing a further O, S or N atom and optionally substituted by

15 a group -(CH₂)_p-R⁶ where p is 0 to 3 and R⁶ is C₁₋₆ alkyl, CONR⁷R⁸ where R⁷ and R⁸ are independently hydrogen, C₁₋₆ alkyl which can optionally contain one or more O, S or NR³ groups, or together with the nitrogen atom to which they are attached form a 5- or 6-membered saturated ring optionally containing a further O, S or NR³ group;

or R⁶ is a 4 to 7-membered saturated ring optionally containing one or more O, S or N

20 atoms, or an aryl or heteroaryl group containing one to four heteroatoms selected from O, S or N, the saturated ring, aryl and heteroaryl groups all being optionally substituted by halogen, amino, hydroxy, cyano, nitro, carboxy, CONR⁷R⁸, SO₂NR⁷R⁸, SO₂R³, trifluoromethyl, NHSO₂R³, NHCOR³, C₁₋₆ alkyl, C₁₋₆ alkoxy, SR³ or NR⁹R¹⁰ where R⁹ and R¹⁰ are independently hydrogen, C₁₋₆ alkyl or together with the nitrogen atom to which they

25 are attached form a 5- or 6-membered saturated ring optionally containing a further O, S or NR³ group;

R³ is hydrogen or C₁₋₆ alkyl;

30 R⁴ is hydrogen or C₁₋₆ alkyl;

R⁵ is hydrogen, C₁₋₆ alkyl or C₃₋₆ cycloalkyl both of which can optionally contain one or more O, S or NR³ groups or R⁵ is aryl or a 5- or 6-membered heteroaryl group containing one or two heteroatoms selected from O, S or N, the aryl and heteroaryl groups all being optionally substituted by halogen, amino, hydroxy, cyano, nitro, carboxy, CONR⁷R⁸,
5 SO₂NR⁷R⁸, SO₂R³, trifluoromethyl, NHSO₂R³, NHCOR³, C₁₋₆ alkyl, C₁₋₆ alkoxy, SR³ or NR⁹R¹⁰ where R⁹ and R¹⁰ are independently hydrogen, C₁₋₆ alkyl or together with the nitrogen atom to which they are attached form a 5- or 6-membered saturated ring optionally containing a further O, S or NR³ group;

10 or R⁴ and R⁵ together form a 5- or 6-membered saturated ring optionally containing a further O, S or NR³ group and optionally substituted by , C₁₋₆ alkyl;

and pharmaceutically acceptable salts or solvates thereof, in the manufacture of a medicament for use in the inhibition of Cathepsin S in a warm blooded animal, such as
15 man.

In the context of the present specification, unless otherwise indicated, an alkyl or alkenyl group or an alkyl or alkenyl moiety in a substituent group may be linear or branched. Aryl groups include phenyl and naphthyl. Heteroaryl groups include 5- or 6-membered, 5,6- or
20 6,6-fused aromatic rings containing one or more heteroatoms selected from N, S, O. Examples include pyridine, pyrimidine, pyrazine, pyridazine, thiazole, oxazole, pyrazole, imidazole, furan and thiophene, quinoline, isoquinoline, benzimidazole, benzofuran, benzothiophene, indole.

25 Certain compounds of formula (I) are capable of existing in stereoisomeric forms. It will be understood that the invention encompasses all geometric and optical isomers of the compounds of formula (I) and mixtures thereof including racemates. Tautomers and mixtures thereof also form an aspect of the present invention.

30 Suitably A is a 6-membered ring optionally containing a double bond and optionally containing an oxygen atom or NR group in the ring where R is hydrogen or C₁₋₆ alkyl. A double bond can be present in any suitable position of the ring A. An oxygen atom or NR group can be present in any suitable position of the ring A, in addition to a double bond if desired. Preferably A is a cyclohexane ring.

Preferably R^1 and R^2 together with the nitrogen atom to which they are attached form an unsubstituted morpholine ring or a piperidine or piperazine ring substituted by a group – $(CH_2)_p-R^6$ where p and R^6 are as defined above. Preferably p is 0 and R^6 is aryl or heteroaryl optionally substituted as defined above.

Preferably R^3 is hydrogen.

Preferably R^4 is hydrogen.

Preferably R^5 is hydrogen, phenyl optionally substituted by C_{1-6} alkyl or C_{1-6} alkoxy

Preferred compounds of the invention include:

(1R,2R)-N-[Cyano(2-methoxyphenyl)methyl]-2-(morpholin-4-ylcarbonyl)cyclohexanecarboxamide,

(1R,2R)-N-[Cyano(2-methoxyphenyl)methyl]-2-{{[4-(4-fluorobenzyl)piperazin-1-yl]carbonyl}cyclohexane carboxamide,

(1R,2R)-N-[Cyano(2-methoxyphenyl)methyl]-2-(3,4-dihydroisoquinolin-2(1H)-ylcarbonyl)cyclohexane carboxamide,

(±) Trans-N-(cyanomethyl)-2-{{[4-(4-fluorobenzyl)piperazin-1-yl]carbonyl}cyclohexanecarboxamide,

(±) Trans-N-[cyano(2-methoxyphenyl)methyl]-2-[(4-methylpiperazin-1-yl)carbonyl]cyclohexanecarboxamide,

(1R,2R)-N-[Cyano(2-methoxyphenyl)methyl]-2-{{[4-(4-fluorophenyl)piperazin-1-yl]carbonyl}cyclohexane carboxamide,


(1R,2R)-N-(4-Cyano-1-methylpiperidin-4-yl)-2-{{[4-(4-fluorophenyl)piperazin-1-yl]carbonyl}cyclohexane carboxamide,

(1R,2R)-N-(4-Cyanotetrahydro-2H-pyran-4-yl)-2-{{[4-(4-fluorophenyl)piperazin-1-yl]carbonyl}cyclohexane carboxamide,

(1R,2R)-N-[(1S)-1-cyano-3-methoxypropyl]-2-{{[4-(4-fluorophenyl)piperazin-1-yl]carbonyl}cyclohexanecarboxamide,

and pharmaceutically acceptable salts thereof.


The present invention further provides a process for the preparation of a compound of formula (I) which comprises reaction of a compound of general formula (II) with a dehydrating agent (e.g. phosphorous oxychloride)



Compounds of formula (II) may be prepared from compounds of formula (III) by activation of the acid with an appropriate coupling agent or formation of acid chloride followed by reaction with an amine $\text{HNR}^3(\text{CR}^4\text{R}^5)\text{CONH}_2$ where R^3 , R^4 and R^5 are defined in formula (I)

reaction of a compound of general formula (III) by activation of the acid group with an appropriate coupling agent or formation of acid chloride followed by reaction with an amine $\text{HNR}^3(\text{CR}^4\text{R}^5)\text{CN}$ where R^3 , R^4 and R^5 are defined in formula (I)

reaction of a compound of general formula (IV), where $\text{X} = \text{CN}$ or CONH_2 , by activation of the acid group with an appropriate coupling agent or formation of acid chloride followed by reaction with an amine HNR^1R^2 where R^1 and R^2 are defined in formula (I)




Compounds of general formula (III) and (IV) may be prepared from compound of general formula (V) by reaction with an amine of general formula $\text{HNR}^3(\text{CR}^4\text{R}^5)\text{CN}$, $\text{HNR}^3(\text{CR}^4\text{R}^5)\text{CONH}_2$ where R^3 , R^4 and R^5 are defined in formula (I) or HNR^1R^2 where R^1 and R^2 are defined in formula (I).

5

Compounds of general formula (III) and (IV) may also be prepared from a compound of general formula (VI) by activation of the acid group with an appropriate coupling agent or formation of acid chloride followed by reaction with an amine of general formula $\text{HNR}^3(\text{CR}^4\text{R}^5)\text{CN}$, $\text{HNR}^3(\text{CR}^4\text{R}^5)\text{CONH}_2$ where R^3 , R^4 and R^5 are defined in formula (I) or HNR^1R^2 where R^1 and R^2 are defined in formula (I) followed by hydrolysis of the ester.

10



15

According to a further feature of the invention there is provided a compound of the formula (I), or a pharmaceutically acceptable salt thereof, for use as a therapeutic agent.

20

According to a further feature of the present invention there is provided a method for producing inhibition of a cysteine protease in a warm blooded animal, such as man, in need of such treatment, which comprises administering to said animal an effective amount of a compound of the present invention, or a pharmaceutically acceptable salt thereof. In particular the compounds of the invention are useful in the treatment of inflammation and immune disorders such as, but not limited to, asthma, rheumatoid arthritis, COPD, multiple sclerosis, Crohn's disease, Alzheimers and pain, such as neuropathic pain. Preferably the compounds of the invention are used to treat pain, especially neuropathic pain.

25

The invention also provides a compound of the formula (I), or a pharmaceutically acceptable salt thereof, for use as a medicament; and the use of a compound of the formula (I) of the present invention, or a pharmaceutically acceptable salt thereof, in the

30

manufacture of a medicament for use in the inhibition of a cysteine protease in a warm blooded animal, such as man.

In particular the invention provides the use of a compound of the formula (I) of the present invention, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in the inhibition of Cathepsin S in a warm blooded animal, such as man. In order to use a compound of the formula (I) or a pharmaceutically acceptable salt thereof for the therapeutic treatment of mammals including humans, in particular in the inhibition of a cysteine protease, it is normally formulated in accordance with standard pharmaceutical practice as a pharmaceutical composition.

Therefore in another aspect the present invention provides a pharmaceutical composition which comprises a compound of the formula (I) or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable diluent or carrier.

15

The pharmaceutical compositions of this invention may be administered in standard manner for the disease condition that it is desired to treat, for example by oral, rectal or parenteral administration. For these purposes the compounds of this invention may be formulated by means known in the art into the form of, for example, tablets, capsules, aqueous or oily solutions or suspensions, (lipid) emulsions, dispersible powders, suppositories, ointments, creams, drops and sterile injectable aqueous or oily solutions or suspensions.

25

A suitable pharmaceutical composition of this invention is one suitable for oral administration in unit dosage form, for example a tablet or capsule which contains between 100 mg and 1 g of the compound of this invention.

In another aspect a pharmaceutical composition of the invention is one suitable for intravenous, subcutaneous or intramuscular injection.

30

Each patient may receive, for example, an intravenous, subcutaneous or intramuscular dose of 1 mgkg^{-1} to 100 mgkg^{-1} of the compound, preferably in the range of 5 mgkg^{-1} to 20 mgkg^{-1} of this invention, the composition being administered 1 to 4 times per day. The intravenous, subcutaneous and intramuscular dose may be given by means of a bolus injection. Alternatively the intravenous dose may be given by continuous infusion over a period of time. Alternatively each patient will receive a daily oral dose which is

35

approximately equivalent to the daily parenteral dose, the composition being administered 1 to 4 times per day.

5 The following illustrate representative pharmaceutical dosage forms containing the compound of formula (I), or a pharmaceutically-acceptable salt thereof (hereafter compound X), for therapeutic or prophylactic use in humans:

(a)

<u>Tablet I</u>	<u>mg/tablet</u>
Compound X.	100
Lactose Ph.Eur.	179
Croscarmellose sodium	12.0
Polyvinylpyrrolidone	6
Magnesium stearate	3.0

(b)

<u>Tablet II</u>	<u>mg/tablet</u>
Compound X	50
Lactose Ph.Eur.	229
Croscarmellose sodium	12.0
Polyvinylpyrrolidone	6
Magnesium stearate	3.0

5

(c)

<u>Tablet III</u>	<u>mg/tablet</u>
Compound X	1.0
Lactose Ph.Eur.	92
Croscarmellose sodium	4.0
Polyvinylpyrrolidone	2.0
Magnesium stearate	1.0

(d)

<u>Capsule</u>	<u>mg/capsule</u>
Compound X	10
Lactose Ph.Eur.	389
Croscarmellose sodium	100
Magnesium stearate	1.

(e)

<u>Injection I</u>	<u>(50 mg/ml)</u>
Compound X	5.0% w/v
Isotonic aqueous solution	to 100%

Buffers, pharmaceutically-acceptable cosolvents such as polyethylene glycol, polypropylene glycol, glycerol or ethanol or complexing agents such as hydroxy-propyl β cyclodextrin may be used to aid formulation.

5 Note

The above formulations may be obtained by conventional procedures well known in the pharmaceutical art. The tablets (a)-(c) may be enteric coated by conventional means, for example to provide a coating of cellulose acetate phthalate.

10 The following examples illustrate the invention.

Example 1**(1R,2R)-N-[Cyano(2-methoxyphenyl)methyl]-2-(morpholin-4-ylcarbonyl)cyclohexanecarboxamide****(i) (1R,2R)-2-([Cyano(2-methoxyphenyl)methyl]amino)carbonyl cyclohexanecarboxylic acid**

A mixture of (3aR,7aR)-hexahydro-2-benzofuran-1,3-dione (3.64g), N,N-diisopropylethylamine (7.63g) and (\pm) 2-(2-methoxyphenyl)aminoacetonitrile hydrochloride (4.7g) in tetrahydrofuran (50ml) was stirred at room temperature for 6 hours. The solvent was removed under reduced pressure and the residue dissolved in water. The cooled (0°C) aqueous solution was acidified by dropwise addition of dilute aqueous hydrochloric acid and the resultant mixture extracted with ethyl acetate. The organic layer was washed with aqueous brine, dried (MgSO₄), and evaporated under reduced pressure. The residue was purified by titration with diethyl ether (100ml) followed by ethyl acetate (3 x 30ml). Yield 1.5g

MS: APCI(+ve) 317(M+1)

(ii) (1R,2R)-N-[Cyano(2-methoxyphenyl)methyl]-2-(morpholin-4-ylcarbonyl)cyclohexanecarboxamide

A solution of the product from step (i) (0.35g), morpholine (0.14g), N,N-diisopropylethylamine (0.36g) and 1-hydroxybenzotriazole (0.22g) in tetrahydrofuran (10ml) was treated with N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride (0.32g) and stirred for 6 hours at room temperature. The mixture was partitioned between ethyl acetate and aqueous brine, the organics dried (MgSO₄) and evaporated under reduced pressure. The residue was purified by chromatography on silica, eluting with a mixture of ethyl acetate (75%) and isohexane (25%). Yield 0.05g

MS: APCI(+ve) 386(M+1)

¹H NMR: (CDCl₃) δ 7.37-7.29(2H, m), 6.96-6.92(3H, m), 6.07(1H, d), 3.97(3H, s), 3.53-3.28(6H, m), 3.16-3.12(2H, m), 2.77-1.63(2H, m), 1.95(1H, d), 1.84-1.58(4H, m), 1.46-1.26(3H, m).

5 Examples 2 and 3

Examples 2 and 3 were prepared according to the general method of example 1 using the appropriate amines

Example 2

10 **(1R,2R)-N-[Cyano(2-methoxyphenyl)methyl]-2-[[4-(4-fluorobenzyl)piperazin-1-yl]carbonyl]cyclohexane carboxamide.**

MS: APCI(+ve) 493(M+1)

¹H NMR: (CDCl₃) δ 7.37-7.21(4H, m), 7.03-6.92(5H, m), 6.06(1H, d), 3.96(3H, s), 3.36-
15 3.31(5H, m), 3.20-3.10(1H, m), 2.73-2.66(2H, m), 2.29-2.25(2H, m), 2.20-2.12(1H, m), 1.95-1.60(6H, m), 1.40-1.20(3H, m).

Example 3

20 **(1R,2R)-N-[Cyano(2-methoxyphenyl)methyl]-2-(3,4-dihydroisoquinolin-2(1H)-ylcarbonyl)cyclohexane carboxamide**

MS: APCI(+ve) 432(M+1)

¹H NMR: (DMSO-d₆) δ 9.06-8.97(1H, m), 7.42-7.32(2H, m), 7.23-6.93(6H, m), 6.03-
25 5.93(1H, m), 4.73-4.38(2H, m), 3.81, 3.73(3H, 2 x s), 3.80-3.40(2H, m), 3.00-2.55(4H, m), 1.92-1.69(4H, m), 1.38-1.17(4H, m).

Example 4

(±) Trans-N-(cyanomethyl)-2-[[4-(4-fluorobenzyl)piperazin-1-yl]carbonyl]cyclohexanecarboxamide

A mixture of (\pm)trans-1,2-cyclohexanedicarboxylic anhydride (0.4g), N,N-diisopropylethylamine (0.34g) and 1-(4-fluorobenzyl)piperazine (0.5g) in tetrahydrofuran (15ml) was stirred at room temperature for 18 hours. At the end of this time the reaction mixture was treated with further N,N-diisopropylethylamine (0.84g) followed by
5 aminoacetonitrile hydrochloride (0.36g), 1-hydroxybenzotriazole (0.53g) and finally N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride (0.75g). The mixture was stirred for 18 hours and subsequently partitioned between ethyl acetate and aqueous sodium bicarbonate, the organics dried (MgSO₄) and evaporated under reduced pressure. The residue was purified by chromatography on silica, eluting with a mixture of
10 triethylamine (0.6%), methanol (2%) and dichloromethane (97.4%). Yield 0.045g

MS: APCI(+ve) 387(M+1)

¹H NMR: (DMSO-d₆) δ 8.46(1H, t), 7.36-7.31(2H, m), 7.17-7.11(2H, m), 4.03(2H, d), 3.50-3.35(6H, m), 2.90-2.80(1H, m), 2.41-2.24(4H, m), 1.80-1.77(1H, m), 1.73-1.65(3H, m), 1.32-1.15(4H, m).
15

Example 5

(\pm) Trans-N-[cyano(2-methoxyphenyl)methyl]-2-[(4-methylpiperazin-1-yl)carbonyl]cyclohexanecarboxamide

20

(i) (\pm) Trans-2-([cyano(2-methoxyphenyl)methyl]amino)carbonyl cyclohexanecarboxylic acid

A mixture of (\pm) trans-1,2-cyclohexanedicarboxylic anhydride (3.0g), N,N-diisopropylethylamine (5.03g) and (\pm) 2-(2-methoxyphenyl)aminoacetonitrile
25 hydrochloride (3.87g) in tetrahydrofuran (50ml) was stirred at room temperature for 18 hours. The solvent was removed under reduced pressure and the residue dissolved in water. The cooled (0°C) aqueous solution was acidified by dropwise addition of dilute aqueous hydrochloric acid and the resultant mixture extracted with ethyl acetate. The organic layer was washed with aqueous brine, dried (MgSO₄), and evaporated under reduced pressure.
30 The residue was purified by titration with ethyl acetate (2 x 30ml). Yield 0.53g

MS: APCI(+ve) 317(M+1)

(ii) (1R,2R)-N-[Cyano(2-methoxyphenyl)methyl]-2-[(4-methylpiperazin-1-yl)carbonyl]cyclohexane carboxamide

A solution of the product from step (i) (0.38g), 1-methylpiperazine (0.18g), N,N-diisopropylethylamine (0.23g) and 1-hydroxybenzotriazole (0.24g) in 1-methyl-2-pyrrolidinone (10ml) was treated with N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride (0.35g) and stirred for 4 hours at room temperature. The mixture was partitioned between ethyl acetate and aqueous sodium bicarbonate, the organics washed with aqueous brine (x3), dried (MgSO₄) and evaporated under reduced pressure. The residue was purified by chromatography on silica, eluting with a mixture of triethylamine (0.4%), methanol (4%) and dichloromethane (95.6%) followed by titration of the resultant product with diethyl ether. Yield 0.035g

MS: APCI(+ve) 399(M+1)

¹H NMR: (DMSO-d₆) δ 8.99(1H, d), 7.44-7.38(2H, m), 7.09(1H, d), 7.00(1H, t), 6.00(1H, d), 3.85(3H, s), 3.44-3.40(2H, m), 2.90-2.82(1H, m), 2.70-2.62(1H, m), 2.24-2.21(2H, m), 2.11-2.08(4H, m), 2.03-2.01(1H, m), 1.87(1H, d), 1.76-1.66(3H, m), 1.36-1.17(4H, m).

Example 6

(1R,2R)-N-[Cyano(2-methoxyphenyl)methyl]-2-[[4-(4-fluorophenyl)piperazin-1-yl]carbonyl]cyclohexane carboxamide

(i) Methyl (1R,2R)-2-[[4-(4-fluorophenyl)piperazin-1-yl]carbonyl]cyclohexanecarboxylate

A solution of (1R, 2R)-cyclohexane 1,2-dicarboxylic acid mono-methyl ester (1.0g) in 1-methyl-2-pyrrolidinone (20ml) was treated with N,N-diisopropylethylamine (1.73g)

followed by 1-(4-fluorophenyl)piperazine (1.45g) and 1-hydroxybenzotriazole (1.09g). The resultant mixture was then treated with N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride (1.55g) and stirred for 18 hours at room temperature. The mixture was partitioned between ethyl acetate and water, the organics washed with water (x3), dried (MgSO₄) and evaporated under reduced pressure. The residue was purified by chromatography on silica, eluting with a mixture of ethyl acetate (45%) and isohexane (55%). Yield 1.4g

MS: APCI(+ve) 349(M+1)

(ii) (1R,2R)-2-{{4-(4-Fluorophenyl)piperazin-1-yl}carbonyl}cyclohexanecarboxylic acid

A solution of the product from step (i) (1.1g) in methanol (40ml) was treated with a solution of sodium hydroxide (0.25g) in water (20ml) and the resultant mixture heated at 50°C for 24 hours. The solvent was removed under reduced pressure and the residue dissolved in water and washed with diethyl ether, the aqueous layer was acidified by addition of glacial acetic acid and extracted with ethyl acetate (x2). The combined ethyl acetate layers were washed with aqueous brine, dried (MgSO₄) and evaporated under reduced pressure. The residue was purified by tritration with diethyl ether. Yield 0.9g

MS: APCI(+ve) 335(M+1)

(iii) (1R,2R)-N-[Cyano(2-methoxyphenyl)methyl]-2-{{4-(4-fluorophenyl)piperazin-1-yl}carbonyl} cyclohexanecarboxamide

A solution of the product from step (iii) (0.35g) in dichloromethane (10ml) at 0°C was treated with (±) 2-(2-methoxyphenyl)aminoacetonitrile hydrochloride (0.25g) and N,N-diisopropylethylamine (0.54g) followed by O-(7-Azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (0.44g). The mixture was stirred at 0°C for 1 hour and then at room temperature for 18 hours. The mixture was partitioned between ethyl acetate and water, the organics washed with water, dried (MgSO₄) and evaporated

under reduced pressure. The residue was purified by chromatography on silica, eluting with a mixture of ethyl acetate (67%) and isohexane (33%). Yield 0.27g

MS: APCI(+ve) 479(M+1)

5 1H NMR: (CDCl₃) δ 7.39-7.23(2H, m), 7.01-6.77(7H, m), 6.06-5.97(1H, m), 3.97-3.95(4H, m), 3.80-3.36(4H, m), 3.19-3.15(1H, m), 3.10-2.47(5H, m), 1.98-1.75(3H, m), 1.65-1.26(4H, m).

Examples 7 and 8

10 Examples 7 and 8 were prepared according to the general method of example 6 step (iii) using the appropriate amines.

Example 7

15 (1R,2R)-N-(4-Cyanotetrahydro-2H-pyran-4-yl)-2-{{[4-(4-fluorophenyl)piperazin-1-yl]carbonyl}cyclohexane carboxamide

MS: APCI(+ve) 443(M+1)

1H NMR: (CDCl₃) δ 7.00-6.94(2H, m), 6.89-6.85(2H, m), 6.32(1H, s), 3.90-3.80(3H, m), 3.78-3.59(5H, m), 3.16-3.12(1H, m), 3.09-3.00(3H, m), 2.92-2.86(1H, m), 2.70-2.64(1H, m), 2.46-2.42(1H, m), 2.22-2.19(1H, m), 1.94-1.82(6H, m), 1.69-1.63(1H, m), 1.49-1.30(3H, m).

Example 8

25 (1R,2R)-N-(4-Cyano-1-methylpiperidin-4-yl)-2-{{[4-(4-fluorophenyl)piperazin-1-yl]carbonyl}cyclohexane carboxamide

MS: APCI(+ve) 456(M+1)

1H NMR: (CDCl₃) δ 7.00-6.94(2H, m), 6.90-6.85(2H, m), 6.20(1H, s), 3.90-3.85(1H, m), 3.80-3.75(1H, m), 3.70-3.60(2H, m), 3.18-3.13(1H, m), 3.09-3.04(3H, m), 2.91-2.85(1H,

m), 2.73-2.61(3H, m), 2.49-2.35(3H, m), 2.29(3H, s), 2.28-2.22(1H, m), 1.90-1.81(6H, m), 1.70-1.60(1H, m), 1.50-1.32(3H, m).

Example 9

(1R,2R)-N-[(1S)-1-cyano-3-methoxypropyl]-2-[[4-(4-fluorophenyl)piperazin-1-yl]carbonyl]cyclohexanecarboxamide

(i) N-2-~(tert-butoxycarbonyl)-O-methyl-L-homoserinamide

A solution of Boc-O-methyl-L-homoserine (7.75g) in dichloromethane (100ml) was treated with carbonyldiimidazole (6.46g) and the mixture stirred for 1h at room temperature. At the end of this time concentrated aqueous ammonia (20ml) was added and stirring continued for a further 40min. The reaction mixture was washed with water followed by dilute aqueous sodium hydroxide and then with aqueous brine before being dried (MgSO₄) and evaporated under reduced pressure. Yield 2.9g

¹H NMR: (DMSO-d₆) δ 7.22(1H, s), 6.94(1H, s), 6.76(1H, d), 3.94-3.88(1H, m), 3.20(3H, s), 1.87-1.83(1H, m), 1.69-1.64(1H, m), 1.38(9H, s).

(ii) O-Methyl-L-homoserinamide hydrochloride

A solution of the product from step (i) (2.9g) in 1,4-dioxane (30ml) was treated with a 4.0 molar solution of HCl in 1,4-dioxane (15ml) and the mixture allowed to stand for 18h at room temperature. The resultant precipitate was filtered off and washed with diethylether. Yield 1.84g

¹H NMR: (DMSO-d₆) δ 8.20(3H, s), 7.94(1H, s), 7.54(1H, s), 3.76(1H, s), 3.46-3.37(2H, m), 3.24(3H, s), 2.05-1.90(2H, m).

(iii) (1R,2R)-N-[(1S)-1-Carboxamide-3-methoxypropyl]-2-[[4-(4-fluorophenyl)piperazin-1-yl]carbonyl]cyclohexanecarboxamide

A solution of the product from step (ii) (0.36g) in 1-methyl-2-pyrrolidinone (15ml) was treated with N,N-diisopropylethylamine (0.93g) followed by (1R,2R)-2-[[4-(4-fluorophenyl)piperazin-1-yl]carbonyl]cyclohexanecarboxylic acid (prepared as described in Example 6, step (ii)) (0.6g). The reaction mixture was cooled to 0°C and treated with O-(7-Azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (0.75g).

The mixture was stirred at 0°C for 1h and then at room temperature for 18h. The mixture was partitioned between ethyl acetate and water, the organics washed with water (x3), dried (MgSO₄) and evaporated under reduced pressure. The residue was purified by trituration with diethylether. Yield 0.40g

MS: APCI(+ve) 449(M+1)

(iv) (1R,2R)-N-[(1S)-1-Cyano-3-methoxypropyl]-2-[[4-(4-fluorophenyl)piperazin-1-yl]carbonyl]cyclohexanecarboxamide

Oxalyl chloride (0.34g) was added dropwise to N,N-dimethylformamide (10ml) at 0°C and the mixture stirred at this temperature for 5 minutes. Pyridine (0.42g) was then added and stirring continued for a further 5 minutes. At the end of this time the mixture was treated dropwise with a solution of the product of step (iii) (0.59g) in N,N-dimethylformamide (5ml). After stirring for 2 hours at 0°C the mixture was partitioned between ethyl acetate and water, the organics washed with water, dried (MgSO₄) and evaporated under reduced pressure. The residue was purified by chromatography on silica, eluting with a mixture of ethyl acetate (80%) and isohexane (20%). Yield 0.21g

MS: APCI(+ve) 431(M+1)

¹H NMR: (DMSO-d₆) δ 8.57(1H, d), 7.08-7.03(2H, m), 6.99-6.94(2H, m), 4.71(1H, q), 3.70-3.58(3H, m), 3.50-3.47(1H, m), 3.37-3.30(2H, m), 3.17(3H, s), 3.08-3.00(3H, m), 2.96-2.89(2H, m), 2.57-2.49(1H, m), 1.98-1.68(6H, m), 1.38-1.20(4H, m).

Measurement of Cathepsin S activity.

QFRET Technology (Quenched Fluorescent Resonance Energy Transfer) was used to measure the inhibition by test compounds of Cathepsin S-mediated cleavage of the synthetic peptide Z-Val-Val-Arg-AMC. Compounds were screened at five concentrations in duplicate and the pIC₅₀ values reported.


Synthetic substrate, 20μM [final]Z-Val-Val-Arg-AMC in phosphate buffer were added to a 96 well black Optiplate. The assay plates were pre-read for compound auto fluorescence on SpectraMax Gemini at 355nm excitation and 460nm emission. 250pM [final] rHuman Cathepsin S in phosphate buffer was added and incubated for 2h at room temperature on

the SpectraMax Gemini, taking readings every 20min at 355nm excitation and 460nm emission.

Activity Based template (5PTB-8) used the auto fluorescent corrected data to calculate the percentage inhibition for each compound concentration using the relevant plate controls. This data was used to construct inhibition curves and pIC_{50} estimated by non-linear regression using a 4 parameter logistic model.

CLAIMS

1. Use of a compound of formula (I):



(I)

10 in which:

A is a 6-membered ring optionally containing a double bond and optionally containing an oxygen atom or NR group in the ring;

R is hydrogen or C₁₋₆ alkyl;

15

R¹ and R² are independently, C₁₋₆ alkyl or C₃₋₆ cycloalkyl both of which can optionally contain one or more O, S or NR³ groups, or R¹ and R² together with the nitrogen atom to which they are attached form a 3,4-dihydroisoquinoline ring or a 5- or 6-membered saturated ring optionally containing a further O, S or N atom and optionally substituted by

20

a group $-(CH_2)_p-R^6$ where p is 0 to 3 and R⁶ is C₁₋₆ alkyl, CONR⁷R⁸ where R⁷ and R⁸ are independently hydrogen, C₁₋₆ alkyl which can optionally contain one or more O, S or NR³ groups, or together with the nitrogen atom to which they are attached form a 5- or 6-membered saturated ring optionally containing a further O, S or NR³ group;

or R⁶ is a 4 to 7-membered saturated ring optionally containing one or more O, S or N

25

atoms, or an aryl or heteroaryl group containing one to four heteroatoms selected from O, S or N, the saturated ring, aryl and heteroaryl groups all being optionally substituted by halogen, amino, hydroxy, cyano, nitro, carboxy, CONR⁷R⁸, SO₂NR⁷R⁸, SO₂R³,

trifluoromethyl, NHSO₂R³, NHCOR³, C₁₋₆ alkyl, C₁₋₆ alkoxy, SR³ or NR⁹R¹⁰ where R⁹ and R¹⁰ are independently hydrogen, C₁₋₆ alkyl or together with the nitrogen atom to which they

30

are attached form a 5- or 6-membered saturated ring optionally containing a further O, S or NR³ group;

R³ is hydrogen or C₁₋₆ alkyl;

R⁴ is hydrogen or C₁₋₆ alkyl;

5

R⁵ is hydrogen, C₁₋₆ alkyl or C₃₋₆ cycloalkyl both of which can optionally contain one or more O, S or NR³ groups or R⁵ is aryl or a 5- or 6-membered heteroaryl group containing one or two heteroatoms selected from O, S or N, the aryl and heteroaryl groups all being optionally substituted by halogen, amino, hydroxy, cyano, nitro, carboxy, CONR⁷R⁸,
10 SO₂NR⁷R⁸, SO₂R³, trifluoromethyl, NHSO₂R³, NHCOR³, C₁₋₆ alkyl, C₁₋₆ alkoxy, SR³ or NR⁹R¹⁰ where R⁹ and R¹⁰ are independently hydrogen, C₁₋₆ alkyl or together with the nitrogen atom to which they are attached form a 5- or 6-membered saturated ring optionally containing a further O, S or NR³ group;

15

or R⁴ and R⁵ together form a 5- or 6-membered saturated ring optionally containing a further O, S or NR³ group and optionally substituted by , C₁₋₆ alkyl;

and pharmaceutically acceptable salts or solvates thereof, in the manufacture of a medicament for use in the inhibition of Cathepsin S in a warm blooded animal, such as
20 man.

2. Use according to claim 1 in which A is a cyclohexane ring.

25

3. Use according to claim 1 or 2 in which R¹ and R² together with the nitrogen atom to which they are attached form an unsubstituted morpholine ring or a piperidine ring substituted by a group -(CH₂)_p-R⁶ where p and R⁶ are as defined in claim 1

4. Use according to any one of claims 1 to 3 in which R³ is hydrogen.

30

5. Use according to any one of claims 1 to 4 in which R⁴ is hydrogen.

6. Use according to any one of claims 1 to 5 in which R⁵ is hydrogen or phenyl optionally substituted by C₁₋₆ alkyl or C₁₋₆ alkoxy.

35

7. Use according to any one of claims 1 to 6 where the compound of formula (I) is selected from:

(1R,2R)-N-[Cyano(2-methoxyphenyl)methyl]-2-(morpholin-4-ylcarbonyl)cyclohexanecarboxamide,

(1R,2R)-N-[Cyano(2-methoxyphenyl)methyl]-2-{[4-(4-fluorobenzyl)piperazin-1-yl]carbonyl}cyclohexane carboxamide,

5 (1R,2R)-N-[Cyano(2-methoxyphenyl)methyl]-2-(3,4-dihydroisoquinolin-2(1H)-ylcarbonyl)cyclohexane carboxamide,

(±) Trans-N-(cyanomethyl)-2-{[4-(4-fluorobenzyl)piperazin-1-yl]carbonyl}cyclohexanecarboxamide,

(±) Trans-N-[cyano(2-methoxyphenyl)methyl]-2-[(4-methylpiperazin-1-yl)carbonyl]cyclohexanecarboxamide,

10 (1R,2R)-N-[Cyano(2-methoxyphenyl)methyl]-2-{[4-(4-fluorophenyl)piperazin-1-yl]carbonyl}cyclohexane carboxamide,

(1R,2R)-N-(4-Cyano-1-methylpiperidin-4-yl)-2-{[4-(4-fluorophenyl)piperazin-1-yl]carbonyl}cyclohexane carboxamide,

15 and pharmaceutically acceptable salts thereof.

8. A compound of formula (I) as defined in any one of claims 1 to 7 for use in therapy.

9. A pharmaceutical composition which comprises a compound of the formula (I) as
20 defined in any one of claims 1 to 7 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable diluent or carrier.

10. A method for producing inhibition of a cysteine protease in a mammal, such as man, in need of such treatment, which comprises administering to said mammal an effective
25 amount of a compound of the present invention as defined in any one of claims 1 to 7, or a pharmaceutically acceptable salt thereof.

11. A method for producing inhibition of a cysteine protease in a mammal, such as man, in need of such treatment, which comprises administering to said mammal an effective
30 amount of a compound as defined in any one of claims 1 to 7, or a pharmaceutically acceptable salt thereof.

12. A method for treating pain, such as neuropathic pain, in a mammal, such as man, in need of such treatment, which comprises administering to said mammal an effective amount of a compound as defined in any one of claims 1 to 7, or a pharmaceutically acceptable salt thereof.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 03/01080

A. CLASSIFICATION OF SUBJECT MATTER

IPC7: C07D 295/182, C07D 211/66, C07D 217/12, C07D 309/32, A61K 31/495,
A61K 31/5375, A61K 31/472, A61P 37/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC7: C07D, A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE,DK,FI,NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

CHEM. ABS DATA

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 2001041700 A1 (YOUNES BEKKALI ET AL), 15 November 2001 (15.11.01), see esp. example 2, and pages 1-2 --	1-12
X	WO 0109110 A1 (BOEHRINGER INGELHEIM PHARMACEUTICALS, INC.), 8 February 2001 (08.02.01), see esp. example 2 and page 5, lines 19-25 -- -----	1-12

☐ Further documents are listed in the continuation of Box C. ☒ See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance
 "E" earlier application or patent but published on or after the international filing date
 "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
 "O" document referring to an oral disclosure, use, exhibition or other means
 "P" document published prior to the international filing date but later than the priority date claimed

"I" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

17 October 2003

Date of mailing of the international search report

22 -10- 2003

Name and mailing address of the ISA/
 Swedish Patent Office
 Box 5055, S-102 42 STOCKHOLM
 Facsimile No. +46 8 666 02 86

Authorized officer

Solveig Gustavsson/EÖ
 Telephone No. +46 8 782 25 00

INTERNATIONAL SEARCH REPORT

Intern application No.
PCT/SE03/01080

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: **10-12**
because they relate to subject matter not required to be searched by this Authority, namely:
see next sheet
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/SE 03/01080

Patent document cited in search report		Publication date		Patent family member(s)		Publication date	
US	2001041700	A1	15/11/01	US	2003087939	A	08/05/03
				US	6313117	B	06/11/01
				CA	2379747	A	08/02/01
				EP	1204652	A	15/05/02
				JP	2003506364	T	18/02/03
				WO	0109110	A	08/02/01

WO	0109110	A1	08/02/01	CA	2379747	A	08/02/01
				EP	1204652	A	15/05/02
				JP	2003506364	T	18/02/03
				US	6313117	B	06/11/01
				US	2001041700	A	15/11/01
				US	2003087939	A	08/05/03

INTERNATIONAL SEARCH REPORT

Internat application No.
PCT/SE03/01080

Claims 10-12 relate to methods of treatment of the human or animal body by surgery or by therapy/ diagnostic methods practised on the human or animal body/Rule 39.1.(iv). Nevertheless, a search has been executed for these claims. The search has been based on the alleged effects of the compounds/compositions.